When compared with secukinumab, an IL-17A inhibitor, in the ECLIPSE trial, a significantly greater proportion of patients with moderate-to-severe psoriasis treated with guselkumab achieved the primary endpoint of at least 90% improvement in PASI (PASI 90) at week 48 (84 vs 70%; P <.0001) (Reich et al, 2019). This evidence concerns the gene IL17A and psoriasis.